Avenue Therapeutics Raises $5 Million in Proceeds through Warrant Exercise Transactions
Miami, January 5, 2024 - Avenue Therapeutics, a specialty pharmaceutical company specializing in the development and commercialization of therapies for neurologic diseases, has announced its entry into warrant exercise agreements with existing accredited investors. Under these agreements, certain outstanding warrants to purchase a total of 16.5 million shares of the company’s common stock will be immediately exercised.
The warrants for immediate exercise include the November 2023 Series B warrants, allowing the purchase of 14.6 million shares of common stock at an exercise price of $0.3006 per share, and the January 2023 warrants, allowing the purchase of 1.9 million shares of common stock at an exercise price of $1.55 per share. However, the exercise price for the January 2023 warrants has been reduced to $0.3006 per share as agreed upon by the company.
Avenue Therapeutics expects the gross proceeds from the warrant exercise transactions to be approximately $5.0 million, before deducting the placement agent fees and estimated offering expenses. The closing of the transactions is anticipated to take place around January 9, 2024, subject to the fulfillment of customary closing conditions.
In related news, Avenue Therapeutics Inc has reported a cumulative net loss of $11 million during the 12-month period ending in the third quarter of 2023. This has resulted in a negative return on assets (ROA) of -246.79%. Comparatively, within the Healthcare sector, 962 other companies have achieved higher return on assets.
Nevertheless, Avenue Therapeutics has seen an improvement in its overall ROA ranking. As of September 30, 2023, the company’s ranking has advanced to 4595 from the previous quarter’s ranking of 4962.
Comments